Keyphrases
Catalonia
100%
Europe
57%
Randomized Controlled Trial
37%
Clinical Pharmacology
34%
Population-based
32%
Colorectal Cancer Risk
29%
Spain
28%
Orphan Medicinal Product
28%
Preoperative Anemia
27%
Clonidine
26%
Clinical Remission
24%
Hypotensive Anesthesia
24%
Dose Reduction
23%
Multi-criteria Decision Analysis
23%
Cancer Medicines
23%
Bleeding
23%
Clinical Treatment
22%
Biosimilar
22%
Electronic Health Records
22%
Long-acting Insulin Analog
22%
Population-based Observational Studies
22%
Critically Ill Patients
22%
Population Analysis
22%
COVID-19 Pandemic
22%
Hospitalization
21%
Clinical Practice
20%
Pharmacological Treatment
20%
Randomized Clinical Trial
20%
Health Technology Assessment
20%
Catalan
20%
Retrospective Analysis
18%
Orphan Drugs
18%
European Countries
18%
Intravenous Iron
18%
Drug Development
18%
Treatment Costs
17%
Anti-tumor Necrosis Factor (anti-TNF)
17%
Suicide Risk
17%
Colorectal Cancer Patients
17%
Asterix
17%
Crohn's Disease
17%
Ankylosing Spondylitis
16%
Endoscopic Sinus Surgery
16%
Inflammatory Bowel Disease
16%
Primary Care
16%
Primary Care Records
15%
Public Health System
15%
Oncology Medicines
15%
Colorectal Cancer
15%
Health Systems
15%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
58%
Observational Study
53%
Clinical Trial
38%
Randomized Controlled Trial
37%
Case-Control Study
31%
Anemia
29%
Colorectal Carcinoma
29%
Remission
29%
Malignant Neoplasm
29%
Adverse Event
28%
Prevalence
28%
Colorectal Cancer
26%
Clinical Pharmacology
25%
Rare Disease
23%
Antibiotics
22%
Spondylarthritis
22%
Disease Activity
18%
Psychotropic Agent
18%
Orphan Drug
18%
Tumor Necrosis Factor Inhibitor
17%
Drug Development
17%
Pandemic
17%
Infection
17%
Ankylosing Spondylitis
16%
Pharmacokinetics
15%
Septic Shock
14%
Replacement Therapy
14%
Ferric Carboxymaltose
14%
Iron Saccharate
14%
Clinical Feature
14%
Hip Fracture
14%
Antivirus Agent
14%
Insulin Analog
14%
Long Acting Insulin
14%
Biosimilar Agent
14%
Osteoarthritis
14%
Inflammatory Bowel Disease
14%
Non-Steroidal Anti-Inflammatory Drug
13%
Crohn's Disease
12%
Clonidine
11%
Tumor Necrosis Factor
11%
Interferon
11%
Clinical Study
11%
Infliximab
11%
Cohort Study
10%
Pharmacotherapy
10%
Antiinfective Agent
9%
Alpha 2 Adrenergic Receptor Stimulating Agent
9%
Bleeding
9%
Randomized Clinical Trial
9%
Medicine and Dentistry
Health Care Cost
49%
Observational Study
40%
Drug Therapy
31%
Randomized Controlled Trial
30%
Case-Control Study
29%
Clonidine
26%
Oncology
26%
Medicine
26%
Randomized Clinical Trial
24%
Functional Endoscopic Sinus Surgery
23%
Anemia
22%
Technology Assessment
22%
Diseases
20%
Health Technology
20%
Crohn's Disease
20%
Malignant Neoplasm
19%
Clinical Trial
17%
Inflammatory Bowel Disease
16%
Drug Dose Reduction
15%
Systematic Review
15%
Bleeding
15%
Spondylarthritis
14%
Ankylosing Spondylitis
14%
Biosimilar
14%
Long Acting Insulin
14%
Insulin Derivative
14%
Osteoarthritis
14%
Hip Fracture
14%
Adverse Event
14%
Decision Making
14%
Nonsteroid Antiinflammatory Agent
13%
Primary Health Care
12%
Outpatient
12%
Colorectal Cancer
11%
Tumor Necrosis Factor
11%
Cancer Surgery
11%
Interferon
11%
Dexmedetomidine
11%
Rare Disease
11%
Disease Activity
10%
TNF Inhibitor
10%
Arm
10%
Remifentanil
10%
Prevalence
10%
Alpha 2 Adrenergic Receptor Stimulating Agent
9%
Drug Use
8%
Targeted Therapy
8%
Infliximab
8%
Infection
8%
COVID-19
8%
